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errors. This has been reported by researchers from several 
countries, in different treatment settings, i.e., clinical trials 
and medical practice, and with different medications. In 
addition, and of particular relevance to the present context, 
these studies covered patients with a wide age range, from 
childhood to very old age.5~’0~12-’ Surprising similarities in 
patterns of medication nonadherence were observed, irre- 
spective of the patients’ ages. For example, real overcompli- 
ance, which means taking higher doses than prescribed for 
longer periods, is no real problem. However, extra doses 
occur infrequently in both young and old patients, as has 
been documented in studies using compliance monitoring 
over periods of several months. Distributions of compliance 
frequencies show that partial compliance is the main prob- 
lem. Thus, there seems to be good evidence that patterns of 
actual medication-taking behavior in older people do not 
differ substantially from those observed in younger patients. 
Why should they? Potential reasons have been studied exten- 
sively, and some answers were outlined and discussed by the 
authors. 
The study of Park et al. had a comprehensive approach 
with regard to understanding nonadherence behavior. How- 
ever, no comment on the relationship between adherence and 
treatment outcome, for example with special regard to arthri- 
tis medication, was mentioned. 
The study had the unique opportunity to analyze com- 
pliance for different medications taken simultaneously by 
patients. The preliminary analyses did not show substantial 
differences in adherence rates across all of these drugs at least 
8 to 10 different groups. This extraordinarily interesting 
result was mentioned but not discussed. It is clear that the 
implications of nonadherence depend on the drugs studied 
and, therefore, necessitate differential analysis.2 
Considering the methodological implications mentioned 
above, it is possible that medication compliance behavior is 
affected little by drug, disease, prognosis, or even symptoms. 
The discussion is somewhat disappointing when recurring to 
often repeated assumptions despite of the results recorded. 
Finally, one question remains: The structural equation model 
of adherence behavior explained 39% of the variance in 
nonadherence; what about the other 60%? Other research- 
ers’ regression models were able to predict 89% of older 
patients with good compliance but only one-third of those 
with poor compliance.20 
One may conclude that some of the pieces of the compli- 
ance puzzle are still missing. With regard to medication 
adherence, older may perhaps be wiser, but why is this so? 
Wolfgang von Renteln-Kruse, MD 
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Editors note: The above letter was referred to the authors 
of the original paper, and their reply follows. 
In reply: The main findings from our recent JAGS article 
(J Am Geriatr Soc 1999; 47:172-183) were that older adult 
rheumatoid arthritis patients were considerably more 
therapy-adherent than younger patients, that there was no 
difference in the adherence rates for arthritis and nonarthritis 
medications, and that the older adults were highly adherent 
despite showing substantial amounts of normal age-related 
cognitive decline. The strongest predictor of nonadherence 
was self-report of being busy and having many unpredictable 
events in one’s life, qualities typical of engaged, middle-aged 
adults. 
Dr. Kruse wonders whether the findings in the present 
study suggest that drug type, disease, or symptoms have no 
effect on medication adherence because we found no evidence 
that any type of medical variable (including dosage fre- 
quency) makes much difference in adherence rates. I think it is 
unlikely that these findings generalize to all diseases, drug 
types, and symptoms. The sample we tested was composed of 
long-term rheumatoid arthritis patients who were taking 
multiple medications for the disease. Because of the potential 
for disability with rheumatoid arthritis as a result of nonad- 
herence, and the fact that most of the drugs prescribed for 
other diseases had a once or twice a day dosing schedule, it 
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would not be difficult to integrate taking medications for 
these other diseases into the existing medication schedule. 
Patients were probed in detail in our study about side effects, 
and they perceived side effects to be almost nonexistent with 
these drugs. This suggests we tested a group of rheumatoid 
arthritis patients who tolerated the drugs they were taking 
well, which would also lead to adherence. 
Regarding the issue of unexplained variance, this is not a 
surprising finding because the total rate of nonadherence for 
the last 2 weeks of monitoring was only 7.5%. This is such a 
low rate of nonadherence that, from a statistical point of 
view, it is quite remarkable that we were able to explain 39% 
of the variance in the data set using our predictors. This low 
amount of nonadherence also resulted in our finding no 
relationship between adherence and treatment outcomes 
(physical mobility, subjective well-being) because adherence 
was so high that there was little possibility of determining if 
nonadherence related to mobility and well-being. 
In later work using this sample, we did find variables 
other than adherence to be important in understanding out- 
comes such as pain and coping. We reported, for example, 
that individuals of lower cognitive function reported more 
pain and poorer mental health than individuals of higher 
ability.’ We also found that patients used adaptive coping 
strategies in this sample when pain was mild but tended to 
catastrophize when pain was severe.2 Thus, we had good 
predictor and outcome measures, but there was simply not 
enough nonadherence to determine effectively the role non- 
adherence might play in important outcomes. Thus, if suffi- 
cient nonadherence were observed in a sample, powerful 
connections might be observed between medical variables 
(e.g., disease severity, number of doses, drug side effects) and 
adherence and between adherence and quality of life mea- 
sures (such as mobility, well-being, and health status). As 
drug regimens are increasingly simplified, however, and pa- 
tients recognize the ability of their drugs to modify disease, 
observing sufficient nonadherence to model such relation- 
ships will be difficult. 
In summary, the good news is that rheumatoid arthritis 
patients take their medications responsibly and that older 
adults are particularly likely to do so. The problems of 
nonadherence in older adults with rheumatoid arthritis seem 
to be vastly overstated in the popular literature. Moreover, 
other studies we have conducted regarding hypertension3 
reinforce this point. However, I should caution that we did 
not study very old adults (the group aged 80 and older), and 
there is some evidence that these individuals are at greater 
risk of nonadherence and that they profit from medication 
organizers and other cognitive  support^.^ In my view, future 
research should focus on adherence in the very old and on 
adherence in recently diagnosed inception samples. 
Denise C.  Park 
The University of Michigan 
Ann Arbor, M I  
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A GEM RISK SCORING PROTOCOL 
To the Editor: Williams and colleagues’ have made an im- 
portant contribution toward development of an instrument 
for identify the appropriate target population for admission 
to GEM units as well as toward describing the associations of 
increased mortality in hospitalized geriatric patients. There 
are several distinct patient populations for whom an instru- 
ment of this type would be useful, such as community- 
dwelling geriatric patients admitted through the emergency 
department, and, as we have at Montefiore, nursing home 
residents cared for by a hospitalist team of geriatricians. 
Although the GEM risk scoring protocol presented in Fig- 
ure 1 in their paper is a preliminary attempt to create an instru- 
ment, it would be helpful if the authors could provide the 
operational definitions that were used in the scoring protocol, 
which appears to have been derived from standard nursing 
assessment documents. Some of the associated factors are dis- 
eases, and others are syndromes or markers for a functional 
impairment. It would be helpful if the authors could elaborate on 
the following: How was depression measured? Were all patients 
who had a Foley catheter on admission scored for this regardless 
of whether the catheter was used for provider convenience, 
measurement of urine output, or for an obstructive uropathy? 
What was the operational definition of “malnutrition?” How 
was dysphagia diagnosed? 
I look forward to additional development of an instru- 
ment such as this which could be validated in subgroups of 
hospitalized geriatric patients. 
Jomarie Zeleznik, MD 
Division of Geriatrics 
Montefiore Medical Center 
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Editors note: The above letter was referred to the authors 
of the original paper, and their reply follows. 
In reply: Zeleznik asks how several items (depression, 
malnutrition, dysphagia) in our risk scoring protocol were 
operationally defined. As stated in our Methods, the three 
most clinically active diagnoses were determined (by MCS, 
who coordinated care on the GEM unit) for each patient. 
There were no set criteria for each diagnosis; rather, they 
were the medical problems judged by the patient’s clinicians 
to have the most import in the patient’s current rehabilitative 
care. As a consequence, when interpreting our risk scoring 
protocol, one must keep in mind that those diagnoses that 
appear on the protocol were primary concerns for these 
patients and not of an incidental nature. 
We did not record the reason for Foley catheter use for 
patients transferred to the GEM unit. 
John R. Meuleman, MD 
Mary Conlin Shaw, PhD, ARNP, CS 
Arthur Williams, PhD 
